C
Clarity Pharmaceuticals Ltd
ASX:CU6
Clarity Pharmaceuticals Ltd
ASX:CU6
Price:
3.635
AUD
1.82%
Market Closed
Market Cap:
AU$1.4B
Relative Value
The Relative Value of one CU6 stock under the Base Case scenario is 0.665 AUD. Compared to the current market price of 3.635 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 82%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CU6
Relative Value
Base Case
0.665
AUD
Overvaluation 82%
C
Multiples Across Competitors
CU6 Competitors Multiples
Clarity Pharmaceuticals Ltd Competitors
Clarity Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
1.4B AUD | 0 | -21 | -18.4 | -18.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
983.7B USD | 15.1 | 47.7 | 32.1 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.2B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
292B CHF | 4.8 | 31 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.5 | 31.9 | 17.6 | 24.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
246.4B CHF | 5.6 | 22.7 | 14 | 17.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
302B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.4 | 9.8 | 11.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 20.2 | 7.5 | 10 | |
| UK |
|
GSK plc
XETRA:GS71
|
104B EUR | 2.8 | 15.8 | 8 | 11.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
